Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Predictive Factors of Intestinal Infraction in Acute Mesenteric Ischemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02645240
Recruitment Status : Completed
First Posted : January 1, 2016
Last Update Posted : August 29, 2017
Sponsor:
Information provided by (Responsible Party):
Mansoura University

Brief Summary:
The study aims to identify several factors that can accurately predict the incident of intestinal infraction in patients with mesenteric vascular occlusion or ischemia.

Condition or disease Intervention/treatment Phase
Mesenteric Ischemia Drug: Heparin injection Phase 4

Detailed Description:
The study aims to identify several clinical, laboratory, and radiologic factors that can accurately predict the occurrence of intestinal infraction in patients with mesenteric vascular occlusion or ischemia in order to prevent unnecessary surgical intervention in patients with just intestinal ischemia and to hasten intervention in patients with actual intestinal gangrene.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 97 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Predictive Factors of Intestinal Infraction in Patients With Acute Mesenteric Ischemia
Study Start Date : October 2015
Actual Primary Completion Date : July 2017
Actual Study Completion Date : August 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Blood Thinners

Arm Intervention/treatment
Experimental: Heparin injection
Injection of low molecular weight heparin in patients with acute mesenteric ischemia to assess outcome
Drug: Heparin injection
Intravenous heparin injection in patients with acute mesenteric ischemia and evaluating their response within 24 hours
Other Name: Low molecular weight heparin injection




Primary Outcome Measures :
  1. Clinical improvement [ Time Frame: 48 hours ]
    Number of patients with resolved abdominal symptoms and incidence of patients developing shock



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 85 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with acute mesenteric Ischemia

Exclusion Criteria:

  • Patients with other causes of acute abdomen other than mesenteric Ischemia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02645240


Locations
Layout table for location information
Egypt
Mansoura university hospital
Mansoura, Dakahlia, Egypt
Sponsors and Collaborators
Mansoura University
Investigators
Layout table for investigator information
Principal Investigator: Sameh H Emile, M.D Mansoura Univesity

Layout table for additonal information
Responsible Party: Mansoura University
ClinicalTrials.gov Identifier: NCT02645240     History of Changes
Other Study ID Numbers: mansoura30
First Posted: January 1, 2016    Key Record Dates
Last Update Posted: August 29, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Layout table for MeSH terms
Ischemia
Mesenteric Ischemia
Pathologic Processes
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Peritoneal Diseases
Vascular Diseases
Cardiovascular Diseases
Heparin
Calcium heparin
Heparin, Low-Molecular-Weight
Dalteparin
Anticoagulants
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action